Showing results (151-160 of 192) with videos related to
Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2016
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)Eric Padron, Amy Dezern, Marcio Andrade-Campos, et al.Haematologica|July 10, 2012
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemiaSarah Abu Kar, Anna Jankowska, Hideki Makishima, et al.Leukemia Research|January 19, 2016
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agentsAziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, et al.Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2010
Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromeMohamed A Kharfan-Dabaja, Julio C Chavez, Daohai Yu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant ErythropoietinAlan F List, Zhuoxin Sun, Amit Verma, et al.The Lancet. Oncology|December 9, 2016
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control studyNancy K Gillis, Markus Ball, Qing Zhang, et al.Journal of Hematology & Oncology|June 28, 2017
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.Cancer|November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research ConsortiumElias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.Biopreservation and Biobanking|November 28, 2017
Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG ReportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.Pageof 20